Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment

NCT04820023 PHASE1, PHASE2 TERMINATED Results posted

This clinical trial is the first-in-human study of BBT-176. The purpose of this trial is to investigate the safety and tolerability of BBT-176 (Part 1) and to evaluate the anti-tumor activity of BBT-176 (Part 2).

Details

Lead sponsor	Bridge Biotherapeutics, Inc.
Phase	PHASE1, PHASE2
Status	TERMINATED
Enrolment	45
Start date	Fri Apr 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Nov 29 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• NSCLC

Interventions

• BBT-176, QD
• BBT-176, BID

Countries

South Korea